Nanosys

Nanomal, a European Union-funded public-private consortium developing a handheld device for rapid, point-of-care molecular diagnosis of malaria and drug resistance, said this week that the instrument is a year ahead of schedule and will be ready for field testing later this year.

QuantumDx is heading a UK-based public-private partnership to develop a chip-based molecular profiling tool for diagnosing and staging cancer, and potentially guiding oncology treatments.

Tech Transfer Tidbits

Premium

Pfizer and UCL to develop stem-cell therapies for AMD; Clarient licenses breast cancer biomarkers from Indiana U; Nanosys and Harvard to outlicense nanowire IP; Luminex settles with SUNY and U of Illinois, and more …

Short Reads

Premium

Life Technologies, J. Craig Venter Institute, BioNanomatrix, Nanosys, Geospiza, HDF Group, Pressure BioSciences, Cofactor Genomics, Ambry Genetics, Affymetrix, Navigenics, Enzymatics, New York State Department of Health, University of Washington

Life Technologies is looking to expand uses of its quantum dot technology beyond life sciences and into applied fields, such as counterfeit detection.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.